Opinion

Video

Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies

Panelists discuss how the substantial financial impact of amyloid-targeting therapies necessitates innovative approaches including value-based pricing models, outcomes-based contracts, risk-sharing arrangements between payers and manufacturers, stratified patient selection criteria, and system-level solutions to balance clinical benefit with economic sustainability for health care systems, insurers, and patients.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
2 experts in this video
Dr Sundar Jagannath
1 expert in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo